Gilead CEO Daniel O'Day on acquisition of cancer drugmaker Immunomedics

Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead's availability of cancer treatments, the companies announced on Sunday. Daniel O'Day, Gilead chairman and CEO, joins "Squawk Box" to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: cnb.cx/2NGeIvi » Subscribe to CNBC TV: cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: www.cnbc.com/ Follow CNBC on LinkedIn: cnb.cx/LinkedInCNBC Follow CNBC News on Facebook: cnb.cx/LikeCNBC Follow CNBC News on Twitter: cnb.cx/FollowCNBC Follow CNBC News on Instagram: cnb.cx/InstagramCNBC For info on the best credit cards go to CNBC Select: www.cnbc.com/select/best-credit-cards/ #CNBC #CNBCTV

• #news_politics
• #squawk_box_us
• #cnbc
• #business_news
• #finance_stock
• #stock_market
• #news_channel
• #news_station
• #breaking_news
• #us_news
• #world_news
• #cable
• #cable_news
• #finance_news
• #money
• #money_tips
• #financial_news
• #stock_market_news
• #stocks